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Abstract 
Rat Precision-Cut Intestinal Slices (PCIS) were evaluated as ex vivo model to study the 
regional gradient of P-gp activity, and to investigate whether the rank order of inhibitory 
potency of P-gp inhibitors can be correctly reproduced in this model with more accurate IC50 
values than with current in vitro models. PCIS were prepared from small intestine (duodenum, 
jejunum, ileum) and colon. Rhodamine 123 (R123) was used as P-gp substrate, while 
verapamil, cyclosporine A, quinidine, ketoconazole, PSC833 and CP100356 were employed 
as P-gp inhibitors. Increase in tissue accumulation of R123 in the presence of the inhibitors 
was considered as an indication of the inhibitory effect. The P-gp inhibitors increased the 
tissue accumulation of R123 in a concentration dependent manner. Fluorescence microscopy 
elucidated that this increase occurred predominantly in the enterocytes. The rank order of the 
corresponding IC50 values agreed well with reported values from cell lines expressing rat P-gp. 
The activity of and inhibitory effects on P-gp were significantly higher in ileum compared to 
the other regions. These data suggest that rat PCIS are a reliable ex vivo model to study the 
activity of intestinal P-gp and the inhibitory effect of drugs. PCIS have potential as ex vivo 
model for the prediction of transporter-mediated drug-drug interactions. 
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1. Introduction 
The intestine is the ma in location for drug absorption after oral administration. Its role 
in drug metabolism, excretion and toxicity has been intens ive ly studied and is well 
acknowledged in the last decade [1-3]. Although many drugs are ma inly absorbed by 
passive diffus ion, intestinal transporters are also invo lved in this process. Located on 
the apical membrane of intestina l epithe lial ce lls, influx transporters, such as members 
of the solute carrier (SLC) super-family, facilitate intestina l absorption. Efflux 
transporters on the apical membrane of the enterocytes, mainly belonging to the 
ATP-bind ing cassette (ABC) family, excrete their substrates from the cells into the 
intestina l lumen, thereby lowering the intracellular concentration and decreasing 
intestina l absorption [4-6]. Thus, this influence of drug transporters on the oral 
absorption must be taken into account in drug development. Particular ly the apical 
efflux transporters with broad substrate  specific ity limit absorption thereby exerting a 
large impact on bioavailability [7, 8]. The three major types of ABC transporters 
expressed on the apical side of the epithelia l cells, namely mult idrug resistance protein 
(MDR1/P-gp), mult idrug resistance-  associated protein 2 (MRP2) and breast cancer 
resistance protein (BCRP), actively excrete their substrates, including drugs, back into 
the gut lumen and thus form a protective barrier in the intestine [5, 7]. Among these 
transporters, P-gp plays a key role due to its broad substrate specific ity and high 
expression level. Furthermore, since many drugs are P-gp substrates and/or inhibitors, 
drug-drug interactions (DDIs) related to P-gp activity occur frequently [9, 10]. Since 
P-gp activity influences both the intracellular concentration of xenobiotics and its 
metabolites in the intestine but also determines the systemic exposure to these 
compounds, prediction of inhib itory potency of (new) drugs is highly important for the 
safety assessment of P-gp substrates. Furthermore, it is important to take into account 
the regional d ifferences in P-gp expression and activity in the various parts of the 
intestine, because this is an important determinant of local exposure to xenobiotics.      
To study the activity of intestina l transporters, several in v itro models have been 
developed, such as membrane vesicles, cell lines, everted gut sac, intestinal perfus ion 
and Ussing chamber [4, 11-13]. However, none of these models can fully represent the 
properties of the intestine with respect to the in v ivo gradient of expression along the  
length of the intestine, and at the same time, serve as a fast and effic ient screening 
method. To meet these challenges, we invest igated whether the rat precision-cut 
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intestina l slices (PCIS) model could be used to study the activity of intest ina l 
transporters. Precisely sliced from the intest ine immed iately after harvesting the tissue, 
PCIS represent an ex v ivo mini-organ model which contains all types of intestinal cells  
in the ir natura l environment, i.e. in v ivo 3D structure with intact intercellular and 
cell-matr ix interactions. They have been successfully used in the investigat ion of drug 
metabolism and toxicity in the intestine [14-20]. The localizat ion along the length of 
the intestine and the regulat ion of some of the transporters were studied on mRNA 
leve l before [21]. To date, studies on the functional activity of these transporters ex 
v ivo is limited to the study of Possidente et al. who investigated the interactions of 
xenobiotics with Mrp2 and P-gp in rat PCIS with calcein-AM as a probe and concluded 
that rat PCIS are a reliable system to study interaction of xenobiotics with these 
transporters [22]. However in this paper only jejunum slices were studied and 
information on the activity in the different regions of the intestine was  lacking. In 
addition the cells involved in the accumulation of the substrates were not identified.  
The aims of the present study were: (1) to verify the applicat ion of rat PCIS to the study 
the activity o f rat intest ina l P-gp using a P-gp-specific substrate; (2) to identify the  
cells invo lved (3) invest igate the intestinal regional difference with respect to P-gp 
inhib it ion; and (4) to verify whether rat PCIS correctly reflect the inhibitory potency, 
i.e. rank order and IC 5 0 values, of different P-gp inhibitors in the rat intestine ex  v ivo;  
In this study, P-gp was chosen as the targeted transporter for its key role in efflux 
transport in the intestine. R123 was selected as P-gp substrate, because it is only 
excreted by P-gp, but not metabolized by CYP-enzymes, as that might interfere with 
the transport results [23]. Moreover, it is easy to detect with high sensit ivity due to its 
intensive fluorescence [24], which also makes it possible to identify by microscopy the 
increased  accumulat ion of this substrate in the presence of a P-gp inhibitor. Two 
strong and specific third generation P-gp inhib itors, CP100356 and PSC833, were 
employed [25], as well as several drugs well known as classical P -gp inhibitors, 
namely verapamil, cyclosporine A, ketoconazole, and quinidine [26-28]. 
 
2. Materials and Methods 
2.1. Chemicals 
Rhodamine 123, verapamil hydrochloride, cyclosporine A, ketoconazole, quinidine and low 
gelling temperature agarose (type VII-A) were purchased from Sigma-Aldrich (USA). 
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(WME) with glutamax-I, and amphotericin B (fungizone) solution were obtained from 
Invitrogen (UK). HEPES was obtained from MP Biomedicals (Germany).  
The stock solutions were prepared in ethanol (R123), methanol (quinidine) or DMSO 
(verapamil, cyclosporine A, ketoconazole, PSC833 and CP100356).  
 
2.2. Animals 
Male Wistar (HsdCpb:WU) rats weighing ca. 300 - 350 g were purchased from Harlan (Horst, 
the Netherlands). Rats were housed in a temperature- and humidity- controlled room on a 
12/12 h light/dark cycle with free access to food and tap water, and acclimatized at least 7 
days before use. All the animal experiments were approved by the animal ethical committee 
of the University of Groningen. 
 
2.3. Preparation and incubation of rat precision-cut intestinal slices 
Precision-cut intestinal slices were prepared from the three different regions of the rat small 
intestine and from the colon as previously described [15, 29]. Briefly, the rat was anesthetized 
by isofurane around 9 am. After the small intestine and colon were excised and put into 
ice-cold, oxygenated Krebs-Henseleit buffer (containing 10 mM HEPES and 25 mM 
D-glucose, pH 7.4), the rat was sacrificed by bleeding by dissection of aorta. The whole 
intestine was divided into four parts: duodenum, jejunum, ileum and colon (duodenum was 
the segment between 2 and 12 cm and jejunum was between 20 and 40 cm from the pylorus, 
while ileum was the segment of the last 20 cm before the ileocecal junction and colon was the 
segment after the ileocecal junction). A 3-cm-segment was cut from the required part and 
flushed with ice-cold buffer. With one end tightly closed, it was filled with 3 % (w/v) agarose 
solution in 0.9 % NaCl (37 °C) and then cooled in ice-cold buffer, allowing the agarose 
solution to gel. Subsequently, the filled segment was embedded in 37 °C agarose solution in a 
precooled tissue embedding unit (Alabama R&D, USA). After the agarose solution had gelled, 
precision-cut slices (thickness about 300 µm and wet weight about 3-5 mg) were made using 
a Krumdieck tissue slicer (Alabama R&D, USA). 
The slices were incubated individually in a 12-well culture plate (Greiner Bio-One GmbH, 
Austria) with 1.3 ml WME (with glutamax-I), supplemented with D-glucose, gentamicin and 
amphotericin B (final concentration: 25 mM, 50 µg/ml, and 2.5 µg/ml, respectively). The 
culture plates were placed in plastic boxes in a pre-warmed cabinet (37 °C) under humidified 
carbogen (95 % O2 and 5 % CO2) and shaken back and forth approximately 90 times per 
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minute (Reciprocating Shaker 3018, Gesellschaft für Labortechnik GmbH, Germany). 
 
2.4. Viability of the intestinal slice 
Intracellular ATP levels in the intestinal slices were evaluated to judge the overall viability of 
the tissue during incubation in parallel groups [17, 30]. After the intestine was excised from 
the abdomen, three tiny pieces were cut and stored as control of untreated tissue, which was 
used to evaluate the quality of intestine as it is the source of intestinal slices. In addition, three 
freshly prepared slices were stored as controls of 0 h. ATP content was measured in slices 
after 5 hours of incubation with or without R123 (highest concentration: 10 µM). Furthermore, 
to estimate the viability of the slices during incubation with R123 and inhibitors, the ATP 
levels of slices co-incubated with a P-gp inhibitor and/or R123 were measured and compared 
with the levels in control groups. All the ATP samples were snap-frozen in 1 ml of 
preservation solution (70 % ethanol containing 2 mM EDTA, pH 10.9) in liquid N2 
immediately after sampling and then stored at -80 °C until further analysis. ATP was analyzed 
by using the ATP Bioluminescence Assay Kit CLS II (Roche Applied Sciences, Germany) and 
by measuring the luminescence in a Spectramax micro-plate reader (Molecular Devices, USA) 
as described before [17, 31]. 
 
2.5. Kinetics of R123 uptake 
After slices were pre-incubated for 30 min, R123 was added to the incubation medium. To 
study the time-course of the uptake, slices were harvested at 15, 30, 60 and 120 minutes after 
the addition of the substrate, respectively. Furthermore, the effect of the medium 
concentration of R123 on its cellular accumulation was tested by using 0.5, 2 and 10 µM 
R123 that were chosen as low, medium and high concentration based on literature studies. To 
select a suitable concentration to show the P-gp inhibition effect, slices were also incubated 
with these R123 concentrations in the absence or presence of CP100356 (2 µM) for 120 min. 
After incubation, slices were collected and rinsed in blank PBS for 5 min and stored at -20 °C 
until further analysis.  
 
2.6. Inhibition study 
To study the inhibitory effects of P-gp inhibitors, a range of concentrations was used to be 
able to depict the inhibition vs concentration curve and calculate the IC50 value. Therefore, 
several concentrations below and above effective concentration of inhibitors were employed 
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allow sufficient uptake to ensure the presence of the inhibitors in the enterocytes at the 
moment the substrate was added. The incubation time of 2 hours and R123 concentration of 2 
µM were selected based on the results of kinetics study above. 
To study the differences in P-gp activity in the different intestinal regions, slices were 
prepared from duodenum, jejunum, ileum and colon and pre- incubated for 30 min in the 
absence or presence of inhibitor. Quinidine and CP100356 were employed as P-gp inhibitors 
with final concentrations in the range of 0 - 200 µM and 0 - 5 µM, respectively. Thereafter, 
R123 was added into each well, followed by 2-h incubation. 
To compare the inhibitory potency of various P-gp inhibitors, slices from rat ileum were 
incubated with verapamil (0 - 50 µM), cyclosporine A (0 - 20 µM), quinidine (0 - 200 µM), 
ketoconazole (0 - 50 µM), PSC833 (0 - 2 µM) and CP100356 (0 - 5 µM) for 30 min, 
whereafter R123 was added into each well, followed by 2-h incubation. Then, tissue samples 
were harvested and stored as described above. The increase of tissue accumulation of R123 
was considered as an indication of P-gp inhibition. 
The final concentration of the solvents in culture medium was always lower than 1 %, which 
did not influence the viability of the slice (evaluated by intracellular ATP, data not shown) and 
the transport activity (compared to the control group without any of these solvent, data not 
shown). 
 
2.7. Intestinal localization of R123 
Fluorescence microscopy was applied to check the localization of R123 in the intestinal 
epithelial cells and to visualize the increase of its accumulation by the action of P-gp 
inhibitors. Based on the inhibition study, quinidine and CP100356 were selected to represent a 
weak and a strong P-gp inhibitor, respectively. The concentrations of inhibitor were selected 
as such, that at these concentrations >50% inhibition occurred, i.e. quinidine (50 µM) and 
CP100356 (2 µM). After pre- incubation for 30 min with or without P-gp inhibitor, intestinal 
slices made from each region were incubated with R123 (final concentration: 2 μM) for 2 h. 
Then the slices were washed in ice-cold PBS, embedded in Tissue-tek (3 slices in one core) 
and snap-frozen in isopentane placed on dry ice within 30 s. They were stored at -80 °C until 
sections of 8 μm were cut perpendicular to the surface of the slice in a Cryostat (CryostatTM 
NX70, Thermo Scientific, USA) at -20°C. The sections were attached and dried on a glass 
slide, and examined unmounted under a fluorescence microscope (Leica DM4000 B, Leica 
Microsystems, Germany) with a +L5 filter (excitation 480/40 nm, emission 527/30 nm) by 
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using a DC350FX digital camera with QWin software (Leica) at a fixed exposure time (1.2 s). 
Thereafter, they were stained with hematoxylin and eosin as described previously [32]. 
Pictures were taken with light microscope (Olympus BX41, Olympus America Inc., USA) at 
approximately the same areas where pictures of the fluorescence were made. A comparison 
between these two groups of images was made to confirm the localization of R123 in the 
intestine in the absence or presence of P-gp inhibitors. 
 
2.8. R123 measurement  
The slices were homogenized using a Mini-BeadBeater-8 (BioSpec, USA) with 200 µl blank 
WME and 400 µl acetonitrile. After centrifugation for 5 min at 13000 rpm and 4 °C, 150 µl 
supernatant was transferred into a 96-well plate, and the fluorescence of R123 was measured 
with a fluorescence plate reader (Molecular Devices, USA) (excitation/emission wavelength: 
485 nm / 530 nm). The intracellular content of R123 was calculated using a calibration curve 
prepared in a homogenate of blank intestinal slices. 
 
2.9. Protein determination 
The pellet remaining after the ATP assay and the R123 measurement was dried overnight at 
37 °C and dissolved in 200 µl of 5 M NaOH for 30 min. After dilution with H2O to 1 M 
NaOH, the protein content of the samples was determined using the Bio-Rad DC Protein 
Assay (Bio-Rad, Germany) with a calibration curve prepared from bovine serum albumin. 
The protein content of each slice was used to normalize for the size variation of the intestinal 
slices. 
 
2.10. Statistical analysis  
All the experiments were performed with at least three different rats and within each 
experiment all incubations were carried out in triplicate and the results were expressed as 
mean ± SEM. Two-tailed paired Student’s t-test was employed for a two-group comparison, 
while one way ANOVA and two way ANOVA were used to compare multiple groups with one 
factor and two factors, respectively. A difference of p <0.05 was considered as the level of 
significance. 
In the inhibition study with various concentrations of inhibitors, data were normalized to their 
control groups (100 %) and fitted into a log [inhibitor] vs. response curve. The IC50 value of 
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3. Results 
3.1. Viability of the intestinal slices 
As shown in Fig. 1, the ATP level in the control of untreated tissue was 2.7 nmol/mg protein 
whereas the slices directly after preparation had an ATP content of 4.0 nmol/mg protein. After 
incubation for 5 h, the ATP content decreased slightly, but not significantly by 12.5 % 
compared to that in the fresh slices (0 h), until 3.5 nmol/mg protein. This level is comparable 
with that in the untreated tissue and also with that in the fresh slices (P >0.05), indicating that 
the intestinal slices are viable during a 5-hour incubation. In addition, no significant 
difference in ATP content of the slice was observed when R123 (2 or 10 µM) was added, 
suggesting that R123 did not influence the viability of the slice during incubation. 
Furthermore, the slice ATP content after co- incubation for 3 h or 5 h with the P-gp inhibitors 
at the highest concentration used for the inhibition study with or without R123 was found to 
be retained at a similar level as that in control group (data not shown). This indicates that the 
intestinal slices are also viable during the incubation with P-gp inhibitors.  
 
 
Fig. 1  ATP content of the intestine (tissue untreated), fresh PCIS at the start of the incubation, and PCIS after 5 h  
of incubation in the absence or presence of 2 and 10 µM of R123 (n=7 to 9).  Data are presented as Mean ± SEM 
of each group. One way ANOVA with Tukey’s comparison as post-hoc test was employed for the comparison 
between every two groups, no statistical significance was found. 
 
3.2. Intestinal localization of R123 
In jejunum and ileum, the R123 content in the epithelial cells was very low, resulting in a faint, 
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nearly invisible line, contrary to the bottom of villi, crypt cells and muscle layer where the 
staining was more intense (Fig. 2 c&d). This is probably caused by the active efflux of R123 
by P-gp which is mainly expressed in the mature epithelial cells on the villi, resulting in a 
gradient of P-gp expression along the villus axis. In line with this, when P-gp was inhibited by 
quinidine or CP100356, the fluorescence intensity of the epithelium lining clearly increased. 
As shown in Fig. 2, the increase of fluorescence intensity of R123 in the jejunum and ileum 
due to the presence of the P-gp inhibitor occurred predominantly in the villi and not in the 
other intestinal structures. In contrast in duodenum and colon, the effect of P-gp inhibition 
was less noticeable, as there was only a small increase of the fluorescence intensity, which 
probably indicates that much less P-gp is expressed in these segments. 
 
3.3. R123 uptake assays 
3.3.1. Time-dependent uptake 
To determine the time-course of R123 uptake during incubation, intestinal slices from ileum 
were incubated with 0.5 or 2 µM R123 for 15, 30, 60 or 120 min. A relatively low R123 
concentration was chosen in order to avoid saturation of P-gp efflux. As shown in Fig. 3a, the 
R123 uptake in both concentrations was linear between 15 min and 120 min. The extrapolated 
tissue concentration at t=0 min is probably due to the non-specific tissue binding of R123.  
 
3.3.2. Concentration-dependent uptake and the effect of P-gp inhibition 
Based on the results above, we investigated the effects of P-gp inhibition on accumulation of 
R123 at different concentrations during 120 min of incubation (shown in Fig. 3b). When 
incubated with R123 (0.5, 2 or 10 µM), the tissue accumulation of R123 increased linearly 
with the R123 concentration (38.7 ± 10.3, 154.0 ± 33.9, and 797.4 ± 272.7 pmol/mg protein, 
respectively). When P-gp efflux was blocked with CP100356, the R123 accumulation in the 
tissue was enhanced to 77.9 ± 14.4, 330.0 ± 51.4, and 1556.8 ± 189.5 pmol/mg protein, 
respectively, which was significant when the concentration of R123 was 2 µM. These data 
indicate that the R123 uptake in PCIS is concentration dependent and its efflux by P-gp is not 
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Fig. 2 The localizat ion of R123 in the intestine (A, duodenum; B, jejunum;  C, ileum; D, co lon) (left : no inhibitor;  
middle: quin idine 50 µM; right: CP100356 2 µM). Pictures were taken at approximately the same areas of the 




Fig. 3a (left panel) The time course of R123 uptake in PCIS at 0.5 and 2 µM R123 (n=3). Results were 
expressed as mean ± SEM. The fluorescence value of blank slice, which was very low and negligible, was 
included by the calibration curves using an homogenate of untreated slices. 
Fig. 3b (right panel) Concentration-dependent uptake of R123 and the effect of P-gp inhibition by CP100356 (2 
µM) (n=3). Results were expressed as mean ± SEM. Two-tailed paired Student’s t-test was employed for 
comparison between the control and CP100356 group at each R123 concentration . * indicates p<0.05. 
 
3.4. Inhibition study 
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The regional difference of P-gp inhibition was studied with intestinal slices made from 
duodenum, jejunum, ileum and colon co- incubated with R123 and at a range of concentrations 
of quinidine or CP100356. As shown in Fig. 4a&b, the maximum effect of P-gp inhibition by 
quinidine was highest in the ileum (approximately 2.5-fold increase) compared to the 
duodenum, and jejunum (approximately 1.5-fold increase). No effect (CP100356) or highly 
variable (quinidine) P-gp inhibition was shown for colon. However, the IC50 values of 
quinidine and CP100356 were similar for each of the intestinal regions.  
When the absolute concentrations of R123 (without inhibitor) in the slices of the different 
regions are depicted it becomes clear that P-gp is differently expressed in the different regions 
resulting in a lower tissue concentration of R123 in the ileum (high efflux activity) and a high 
tissue concentration in the colon (low efflux activity) (Fig. 5). After P-gp efflux was inhibited 
by either CP100356 or quinidine, R123 accumulation in ileum slices was significantly 




Fig. 4 a&b Effects of P-gp inhibit ion by quinidine and CP 100356 on R123 accumulation in PCIS of the 
different regions along the intestine. The results are expressed as mean ± SEM which are relat ive to the control 
group (no inhibitor), n=3 for duodenum, jejunum and colon, n=6 for ileum (data for ileum include the data for 
CP 100356 and quinidine obtained in the experiments where the six inhibitors were tested). NI, no inhibition .  
 
3.4.2. Inhibitory potencies of various P-gp inhibitors 
The inhibitory potency of six P-gp inhibitors on R123 accumulation in ileum was compared 
using various concentrations of the inhibitors. As shown in Fig. 6, all six inhibitors enhanced 
R123 accumulation in the PCIS concentration-dependently, indicating their inhibition of P-gp. 
An approximately 2.5 to 3.0-fold increase of R123 accumulation at maximum inhibition was 
observed. The inhibition response vs. concentration curves were used to calculate the 
 34 Chapter 2 
corresponding IC50 values. The results clearly indicate that the potency of P-gp inhibition, 
estimated by the IC50 value, varied greatly. PSC833 and CP100356, two potent P-gp inhibitors, 
showed strong inhibition with IC50 values at 0.60 µM and 0.66 µM, respectively. The other 
four classical P-gp inhibitors showed a lower potency of P-gp inhibition: quinidine (23.57 
µM), cyclosporine A (2.34 µM), verapamil (5.21 µM), and ketoconazole (8.22 µM) (Fig. 6 
and Table 1). The IC50 values of these inhibitors found for rat PCIS were generally higher 
than those reported before for rat P-gp expressed in the LLC-PK1 cell line [27]. However, the 
rank order was the same. In contrast, the rank order of inhibition efficacy was different for rat 
and human P-gp, with respect to the rank order of ketoconazole and verapamil, indicating 
species differences in P-gp substrate specificity [25]. 
 
 
Fig. 5 The influence of P-gp inhibit ion by quinid ine and CP100356 on R123 accumulation  in  PCIS of the 
different intestinal regions. The results were expressed as mean ± SEM. N = 3 for duodenum, jejunum and colon, 
n = 6 for ileum (data for ileum include the data for CP 100356 and quin idine obtained in the experiments where 
the six inhibitors were tested). Two-way ANOVA with Bonferron i post-hoc test was used to compare mult iple 
groups with two factors, i.e. reg ion and inhibitor treatment. In the control group, R123 accumulat ion was found 
significantly d ifferent between ileum and colon, however, with P-gp inhibit ion, no regional difference in R123 
accumulat ion was found. Besides, there was a significant increase of R123 accumulat ion after P -gp inhibit ion in  
ileum slices. ns = not significant; ** significant with p<0.01, *** significant with p<0.001 
 
4. Discussion 
Intestina l transporters are major determinants of the absorption, and thus of the 
efficacy and safety profile of drugs and in addition to that, determine the local 
concentration in the intestina l epithelium. There is no doubt that they need to be taken 
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consortium [33]. In this review Caco-2 or P-gp-overexpressing polar ized epithelia l cell 
lines were recommended as methods to screen for drug candidates that are substrates 
and/or inhibitors of transporters, especially P -gp. However, it is generally known that  
cell lines do not express the transporters at physiological leve ls nor can represent the 
different regions of the intestine [34, 35]. The data of the present study show that the 




Fig. 6 Effect of 6 different P-gp inhib itors on R123 accumulat ion in PCIS. The results are expressed as mean ± 
SEM, which was relative to the control group (no inhibitor), n=3 for each inhibitor. 
 
In the past decade we and others have developed PCIS as ex v ivo model to study drug 
metabolism and toxic ity [15-20]. Because PCIS are prepared from fresh tissue, the 
expression of transporters and metabolic enzymes is at physiologica l leve ls. 
Furthermore it is possible to make >100 slices from each region of the intest ine within 
one experiment, thus, the number of animals needed is largely reduced, which is in 
good accordance with the 3Rs (Reduction, Replacement and Refinement). In previous 
studies we have shown that PCIS remain viab le and retain their metabo lic activity for 
at least 8 hours of cultur ing, which is substantia lly longer than other intact tissue  
preparations [15-17]. However the only study on transport up to now was the study of 
Possidente et al. showing the applicability of PCIS for transport studies, but without  
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information on gradients along the length of the intestine and on the cellular  
localization of the accumulated substrates.  








Caco-2 cell line MDCKII cell line 
IC50 
(µM)  rank 
order 
Ki 
(µM)  rank 
order 
IC50 (µM)  rank 
order 
IC50 (µM)  rank 
order 
  Ref. 1 Ref. 2 Ref. 3 Ref. 4 Ref. 5 
PSC833 0.60 1--2 
  
  0.1 0.11 1--2       
CP100356 0.66 1--2     0.1   1--2       
Cyclosporine A 2.34 3 0.038 3 1.2 1.3 3--4 1.6 1.6 3 
Verapamil 5.21 4 0.96 4 2.2 2.1 5--6 10.7 5.9 5 
Ketoconazole 8.22 5 1.41 5 1.2   3--4 3.1 3.7 4 
Quinidine 23.57 6 2.24 6 2.3 2.3 5--6 14.9 14.1 6 
Ref.1: [27]; Ref.2: [25]; Ref.3: [36]; Ref.4: [28]; Ref.5: [26] 
 
In the present study, we used R123 to study P-gp function along the length of the intestine and 
to investigate inhibitory potency of drugs and to identify the cells involved in the transport of 
the P-gp substrate. The accumulation of R123 in PCIS was linear until 120 min, and 
concentration dependent (Fig. 3 a&b). Furthermore, inhibition of P-gp resulted in a further 
increase of the intracellular concentration. This increase was mainly due to increase in R123 
content of the enterocytes as shown by fluorescence microscopy (Fig. 2). Interestingly, it 
appeared that the estimated average concentration of R123 in the tissue was 6-8 times higher 
than the medium concentration after incubation for 2 h. This might be explained by the high 
affinity of R123 to mitochondria and/or the formation of R123 micelles [37]. By this 
intracellular compartmentalization of R123 the cytoplasmic concentration apparently remains 
low, ensuring a driving force for passive diffusion into the cell even when the efflux of R123 
is inhibited.  
The intestine is a heterogeneous organ in which differences in structure and function 
are prominent among its regions. Each of the intestinal efflux transporters has its 
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to now to what extent these expression levels also represent functional differences. A 
discrepancy between protein expression and transport activity can be anticipated as it has been 
demonstrated that the transporters are not solely localized at the plasma membrane but also 
intracellularly, such as in intracellular membrane vesicles [39]. In the present study, we used 
slices from the different intestinal regions to study the regional differences in P-gp activity. It 
should be noted that in vivo there are also other physiological differences between the 
different intestinal regions that were not accounted for in the ex vivo studies. For example the 
pH in the rat intestinal lumen is different in the different regions, but was kept the same (pH 
7.4) in the ex vivo incubations. Nevertheless, the increasing gradient of P-gp activity from 
jejunum to ileum and lower activity in colon was consistent with the reported P-gp expression 
profile. The highest inhibition effect was found in the ileum compared to the duodenum and 
jejunum (Fig. 4). Similarly, using the everted gut sac model, Yumoto et al. observed a higher 
transport rate by P-gp in the ileum than in duodenum and jejunum with a similar fold 
difference as found in the current study [40]. The inhibition effect was lowest in colon, which 
is consistent with the lower P-gp abundance in human colon quantified by mass 
spectrometry-based targeted proteomics [41]. The maximum inhibition effect of the P-gp 
inhibitors was approximately 2 to 2.5 fold in ileum and 1.5 fold in the other regions, which is 
similar to that in vivo [42, 43]. Fenner et al. summarized data from 123 clinical trials where 
P-gp inhibitors were co-administrated with digoxin, and found that the AUC and Cmax 
increased not more than 2 fold [42]. In contrast, with cell lines a 6 - 10 fold decrease in efflux 
rate was commonly found [44]. This suggests that the slices ex vivo mimic the in vivo 
situation better than the cell lines.  
The inhibition potency of P-gp inhibitors, usually estimated by the IC50 value, varies in 
different in vitro models, mainly because of the different intracellular concentrations of the 
inhibitors and the different P-gp substrates used as well as different calculation methods [45]. 
On the other hand, the rank order of inhibition ability is expected to be the same among 
models and different substrates [28, 46]. In the present study, the rank order of the IC50 values 
of the used inhibitors agreed very well with published data on the K i of these compounds for 
rat P-gp. Compared with human cell data, we found a difference in the rank order of 
verapamil and quinidine, which is probably due to a species difference, which is in line with 
the data of Suzuyama et al. who found different relative IC50 values for different animal 
species using quinidine and verapamil as P-gp inhibitors [47]. Since the PCIS technique can 
be applied to human intestine as well [17, 29], it will be very interesting to study the 
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inhibitory potency of inhibitors in human PCIS prepared from human intestine. These 
experiments are currently in progress. 
Nevertheless, the absolute IC50 value is important for correct prediction of DDIs and 
according to the FDA, if the ratio of the systemic steady-state Cmax, [I]1 to its in vitro 
inhibitory potency (Ki or IC50), is ≥ 0.1 a clinical trial should be performed to indicate the risk 
of a DDI for potential P-gp inhibitors. Since the absolute IC50 value is guiding for these 
predictions, it is important that in vitro systems do not only rank the potency of possible P-gp 
inhibitors correctly. If the in vitro IC50 values are lower than in vivo, the predicted values of 
the ratios of [I]1/IC50 are too high. This might be one of the reasons why many false positive 
interactions were found [48].  
The IC50 values of P-gp inhibitors found in our study were substantially higher than found 
with cell lines and P-gp overexpressing cells (Table 1). The cause of the different IC50 values 
could be a different concentration at the target (the transporter) in the different systems. Since 
target concentrations of substrate and inhibitors are influenced by metabolism and 
influx/efflux in the target cells it can be expected that IC50 values are closer to in vivo when 
predicted in a system where transporters and drug metabolizing enzymes are expressed at 
physiological levels and original tissue/organ structure is preserved, such as in PCIS. 
Therefore predictions for DDIs made with the PCIS are possibly more relevant for the in vivo 
situation in the intestine than those obtained with cell lines.  
In the FDA guidelines for DDI prediction, the influence of regional differences in the intestine 
and the overexpression of P-gp in Caco-2 or other P-gp-expressing polarized epithelial cell 
lines are ignored. However, the influence of inhibition on the absorption and as such on the 
AUC of drugs is largely determined by P-gp expression and regional differences are therefore 
relevant. As the majority of drugs is already largely absorbed in duodenum and jejunum 
where P-gp expression is low, systems that highly express P-gp, such as Caco-2 cells might 
overestimate the effect of P-gp inhibitors on AUC in vivo. Furthermore, it should be noted that 
the local exposure to a P-gp substrate in the presence of an inhibitor is largely determined by 
the local P-gp expression itself. The use of PCIS of different intestinal regions can reflect 
these regional differences, and thus represent the physiology of the intestine to a larger extent. 
In conclusion, the present study shows that rat PCIS are a reliable and efficient ex vivo model 
to study the activity of intestinal transporters, and to assess the inhibitory potential of new 
drugs in each of the different regions of the intestine. In addition we confirmed for the first 
time that in the PCIS this inhibitory action is exerted in the enterocytes specifically. The IC 50 
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measured in cell lines, but the absolute values are much higher and expected to be closer to 
the in vivo values. Therefore, the PCIS model has the potential to make a better prediction of 
transporter-mediated DDIs in the intestine and the toxicity derived from this type of DDIs. 
Furthermore, its future application in human intestinal slices could overcome difficulties in 
extrapolation from experimental animals to humans.  
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